In a presentation titled “Biosimilar Medicine: Changing Landscape in Health Care,” given on Monday at the 2017 American College of Rheumatology Annual Meeting in San Diego, California, J. Eugene Huffstutter MD, FACP, FACR, shared practical considerations for using biosimilars in the rheumatology clinic.
In a presentation titled “Biosimilar Medicine: Changing Landscape in Health Care,” given on Monday at the 2017 American College of Rheumatology Annual Meeting in San Diego, California, J. Eugene Huffstutter MD, FACP, FACR, shared practical considerations for using biosimilars in the rheumatology clinic.
Among the potential issues that a physician could encounter with a biosimilar in practice are the following:
However, Huffstutter pointed out that there are other risks associated with a transition to biosimilars, some of which are not discussed as often as the above:
Furthermore, rheumatologists have a steep learning curve ahead. Huffstutter called on rheumatologists to familiarize themselves with state laws governing substitution of interchangeable biosimilars, availability of patient support programs, insurance contracts, formulary status, and—critically—patient acceptance of biosimilars. Patients, he says, have “been left out of this whole discussion.”
But before biosimilars will achieve widespread adoption in rheumatology, the issue of cost must be addressed. Huffstutter shared many rheumatologists’ frustrations about the high cost of biologics, and was bemused by CMS’ wholesale acquisition cost that determines reimbursement for biosimilars. “[I] want CMS to tell us where they get these prices from so I can buy it from there, because it’s certainly a lot cheaper than what I can buy it for,” he said.
Instead of putting the onus for high costs on the drug manufacturers—“not only do we throw [manufacturers] under the bus, we back up and run over them again”—Huffstutter blamed PBMs, who profit from rebates provided by manufacturers in exchange for formulary placement, for potentially blocking biosimilar access. “That’s where the money is…[a manufacturer's profit] is chump change compared to what is going on [with PBMs],” said Huffstutter. “I don’t care how good a rheumatologist you are: if you can’t get a drug to a patient, you’re wasting your time.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.